SecBot SecBot
8-K ·Filed Jul 22, 2026

KROS

Keros Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed3mo ago SEC0001664710-26-000038
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

This is a routine CFO departure with an internal interim replacement and no severance cost, limited near-term stock impact. Monitor the search for a permanent CFO and any subsequent 10-Q filing for financial statement continuity.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$10.14
T+0 close · Jul 22, 2026 · via day close
Latest settled
+9.47%
T+60 · $11.10
Vs SPY
+4.91%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 23 $10.14entry
  2. T+1 · 4mo ago −0.79%α −0.89% · $10.06
  3. T+5 · 4mo ago +0.79%α +0.31% · $10.22
  4. T+20 · 3mo ago +7.99%α +4.68% · $10.95
  5. T+60 · 5w ago +9.47%α +4.91% · $11.10
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CFO Keith Regnante resigned effective August 3, 2026, to pursue other opportunities. Corporate Controller Annita Tanini was appointed interim principal financial and accounting officer effective August 4, 2026, with a base salary of $302,300. The company has commenced a search for a permanent CFO. The departure is stated as voluntary with no disagreement over accounting or operations, and Regnante receives no severance beyond accrued pay and COBRA eligibility.

Key Facts

  • CFO Keith Regnante resigned effective August 3, 2026, to pursue other opportunities.
  • Annita Tanini, Corporate Controller and VP of Finance, appointed interim principal financial and accounting officer effective August 4, 2026.
  • Regnante's resignation is voluntary with no disagreement over accounting, financials, or internal controls.
  • Regnante receives no severance, only accrued base salary, expense reimbursement, and COBRA continuation at his own expense.
  • Tanini's compensation: $302,300 base salary, 30% target bonus, and six months severance on qualifying termination.
  • Company has commenced a search for a permanent CFO.

Financial Impact

No material financial impact disclosed. CFO transition with interim appointment and no severance payout.

Risk Factors

  • Extended CFO vacancy could delay financial reporting or strategic decisions.
  • Interim CFO may lack public company CFO experience, increasing execution risk during the search period.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
64% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001664710-26-000038
Document: 0001664710-26-000038-index-headers.html0001664710-26-000038
Document: 0001664710-26-000038-index.html0001664710-26-000038
Document: 0001664710-26-000038.txt0001664710-26-000038

Track record

27 reports on KROS

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +12.51% at T+60 after the Jul 30, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Neutral 2/10 Entry $10.03 Now $10.03 −0.00% settles Dec 16
  2. Nov 12, 20264d ago 144 Neutral 2/10 Entry $10.30 Now $10.03 −2.62% settles Dec 14
  3. Nov 5, 202611d ago 8-K Neutral 3/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
  5. Nov 5, 202611d ago Press Release Neutral 5/10 No price data
  6. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $11.61 Now $10.03 −13.61% settles Nov 25
  7. Sep 29, 20266w ago 8-K Bullish 6/10 Entry $11.19 to $11.43 Now $10.03 −10.37% ▲ +2.10% +1.39% vs SPY
  8. Sep 28, 20267w ago 8-K Neutral 4/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
  9. Sep 28, 20267w ago Press Release Neutral 3/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
  10. Sep 17, 20268w ago EFFECT Neutral 3/10 Entry $11.36 to $11.10 Now $10.03 −11.71% ▼ −2.29% −3.49% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens in 6h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 22, 2026